SCHEMBL202089

SCHEMBL202089

CC(C)(C)OC(=O)NCCCn1c(=S)[nH]c2cnc3cc(Br)ccc3c21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.44
CAMK2D Q13557 1/20 0.40
PLK1 P53350 3/20 0.40
MAPT P10636 5/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PIM1 P11309 1/20 0.38
PIM3 Q86V86 1/20 0.38
ALDH1A1 P00352 3/20 0.38
GFER P55789 1/20 0.38
CNR2 P34972 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
KMT2A Q03164 2/20 0.37
GAA P10253 1/20 0.37
UBE2N P61088 1/20 0.37
PKM P14618 1/20 0.36
HTT P42858 1/20 0.36
EGFR P00533 1/20 0.36
RAF1 P04049 1/20 0.36
KDR P35968 1/20 0.36
MAP2K2 P36507 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1233021 0.80 DYRK1A (0.45) DYRK1ACAMK2DPLK1PIM1PIM3
SCHEMBL203579 0.79 DYRK1A (0.48) DYRK1ACAMK2DPIM1PIM3CNR2
SCHEMBL203737 0.79 DYRK1A (0.44) DYRK1ACAMK2DPIM1PIM3CNR2
SCHEMBL16748325 0.78 EGFR (0.41) DYRK1ACAMK2DMAPTKMT2AHTT
SCHEMBL1233687 0.76 DYRK1A (0.40) DYRK1ACAMK2DEGFRRAF1KDR
SCHEMBL204290 0.75 BCHE (0.42) DYRK1AALDH1A1GFERBCHEDRD2
SCHEMBL15798230 0.74 DYRK1A (0.56) DYRK1ACAMK2DPLK1PIM1PIM3
SCHEMBL202761 0.73 BCHE (0.40) ALDH1A1GFERKMT2AGAABCHE
SCHEMBL203808 0.71 STK17B (0.44) DYRK1AEGFRRAF1KDRMAP2K2
SCHEMBL23037699 0.70 BCHE (0.41) ALDH1A1GFEREGFRRAF1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088788-B2 Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-01-03 US disclosed
US-20090221551-A1 SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS PFIZER INC. 2009-09-03 US disclosed
WO-2007106852-A2 SUBSTITUTED FUSED[1,2]IMIDAZO[4,5-C] RING COMPOUNDS AND METHODS COLEY PHARMACEUTICAL GROUP, INC. (US) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221551-A1 SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS IL2, IFNG, IL4 DYRK1A 4633/4885CAMK2D 3889/4885PLK1 3234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.